Business Context and Reporting Period
This Form 8-K is a current report filed by Aileron Therapeutics, Inc. (Note: Request metadata listed "Rein Therapeutics," but the filing text identifies the registrant as Aileron Therapeutics, Inc.) on June 11, 2020. The report addresses a specific corporate event regarding the company's listing status on the Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. The report focuses exclusively on regulatory compliance regarding stock price.
Material Changes
The primary material event is the resolution of a listing deficiency. The company previously received a deficiency letter in July 2019 because its common stock closed below the $1.00 minimum bid price requirement for 30 consecutive business days. After transferring from the Nasdaq Global Market to the Nasdaq Capital Market in December 2019 and receiving multiple extensions, the company successfully regained compliance.
Guidance, Outlook, and Risks
On June 11, 2020, the company received a Compliance Letter from Nasdaq confirming that the matter is closed. Compliance was achieved because the common stock maintained a closing bid price of at least $1.00 for ten consecutive trading days between May 28, 2020, and June 10, 2020. The filing contains no forward-looking guidance, management commentary on operations, or discussion of new risks beyond the resolved listing issue.
Investor Verification Checklist
- Verify the company name is Aileron Therapeutics, Inc. (ticker: ALRN), not Rein Therapeutics.
- Confirm the stock price has remained above the $1.00 threshold following the June 10, 2020 compliance date.
- Review the company's financial statements in other filings (e.g., 10-K or 10-Q) as this 8-K contains no financial performance data.
- Monitor future Nasdaq communications to ensure continued compliance with listing standards.